Back to Search
Start Over
Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell Carcinoma.
- Source :
-
Hematology/oncology clinics of North America [Hematol Oncol Clin North Am] 2023 Oct; Vol. 37 (5), pp. 937-942. Date of Electronic Publication: 2023 Jul 03. - Publication Year :
- 2023
-
Abstract
- Patients with metastatic clear cell renal cell carcinoma (mccRCC) experience highly heterogeneous outcomes when treated with standard-of-care systemic regimens. Therefore, valid biomarkers are needed to predict the clinical response to these therapies and help guide management. In this review, the authors outline relevant and promising biomarkers for patients with mccRCC receiving systemic therapies, with a focus on immunotherapy-based regimens.<br /> (Copyright © 2023 Elsevier Inc. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 1558-1977
- Volume :
- 37
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Hematology/oncology clinics of North America
- Publication Type :
- Academic Journal
- Accession number :
- 37407357
- Full Text :
- https://doi.org/10.1016/j.hoc.2023.05.021